Summary
83 / 100 · Bulios Score
What speaks for it
- Out of every 100 CNY of revenue, 20 CNY is left as net profit.
- It earns 20 CNY a year on every 100 CNY of invested capital.
- Earnings per share grew by 18% a year over the last 3 years.
- It holds more cash than debt: ¥743.7M against ¥446.1M.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Drug Manufacturers - Specialty & Generic)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.8 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 8.7% a year. Earnings per share grew by 18% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CNY of revenue goes
- Cost of sales 21 CNY
- Research and development 4.0 CNY
- Sales and administration 52 CNY
- Taxes and other 2.2 CNY
- Net profit 20 CNY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 23 CNY
Out of every 100 CNY of revenue, 20 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, stretched- Yield
- 5.41%
- Paid out of profit
- 80%
You receive ¥1.10 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail